http://www.fpnotebook.com/
TeriparatideAka: Forteo
- Mechanism
- Recombinant Parathyroid Hormone
- Indications
- Osteoporosis (high risk men and postmenopausal women)
- Dose: 20 mcg SQ qd
- Efficacy
- BMD increases 5.9% at spine and 1.5% at femoral neck
- Reduced risk for osteoporotic Fractures
- Contraindications
- Precautions
- Do not use with bisphosphonate
- Use limited to 2 year maximum
- Resources
- National Osteoporosis Foundation Clinicians Guide To Osteoporosis
- References
Teriparatide (C0070093) | |
|---|---|
| Definition (MSH) | A polypeptide that consists of the 1-34 amino-acid fragment of human PARATHYROID HORMONE, the biologically active N-terminal region. The acetate form is given by intravenous infusion in the differential diagnosis of HYPOPARATHYROIDISM and PSEUDOHYPOPARATHYROIDISM. (Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1995) |
| Concepts | Amino Acid, Peptide, or Protein (T116) , Pharmacologic Substance (T121) |
| MSH | D019379 |
| English | HPTH 001 034, Teriparatide, TERIPARATIDE @ @ UNIDENTIFIED, TERIPARATIDE PREPARATION, TERIPARATIDE UNIDENTIFIED |
| Spanish | teriparatida, teriparatide |
| Parent Concepts | Parathyroid Hormones (C0030520), Recombinant Growth Factor (C1515377), Parathyroid gland (C0030518), [DX900] DIAGNOSTICS, OTHER (C0973537), Unclassified Ingredients (C1372954), Diagnostic agents (C0358514), Polypeptides (C1305923), Calcium regulating hormone (C0360589) |
| Sources | MSH, MTHSPL, NCI, NDFRT, RXNORM, SCTSPA, SNOMEDCT, USPMG, VANDF Derived from the NIH UMLS (Unified Medical Language System) |
Forteo (C1170286) | |
|---|---|
| Concepts | Amino Acid, Peptide, or Protein (T116) , Pharmacologic Substance (T121) |
| MSH | D019379 |
| English | Forteo, Lilly Brand of Teriparatide, Teriparatide Lilly Brand |
| Sources | MSH, RXNORM Derived from the NIH UMLS (Unified Medical Language System) |
